CN1929855A - 诱导或调节免疫反应的方法 - Google Patents

诱导或调节免疫反应的方法 Download PDF

Info

Publication number
CN1929855A
CN1929855A CNA2005800072757A CN200580007275A CN1929855A CN 1929855 A CN1929855 A CN 1929855A CN A2005800072757 A CNA2005800072757 A CN A2005800072757A CN 200580007275 A CN200580007275 A CN 200580007275A CN 1929855 A CN1929855 A CN 1929855A
Authority
CN
China
Prior art keywords
axotrophin
polynucleotide
polypeptide
coding
polypeptides derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800072757A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊·玛丽亚·梅特卡夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ekra Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1929855A publication Critical patent/CN1929855A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CNA2005800072757A 2004-01-29 2005-01-31 诱导或调节免疫反应的方法 Pending CN1929855A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402051.7A GB0402051D0 (en) 2004-01-29 2004-01-29 Fate determination in immunity
GB0402051.7 2004-01-29

Publications (1)

Publication Number Publication Date
CN1929855A true CN1929855A (zh) 2007-03-14

Family

ID=31971742

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800072757A Pending CN1929855A (zh) 2004-01-29 2005-01-31 诱导或调节免疫反应的方法

Country Status (10)

Country Link
US (2) US20070286807A1 (enExample)
EP (1) EP1713495A2 (enExample)
JP (1) JP2007523640A (enExample)
KR (1) KR20070007291A (enExample)
CN (1) CN1929855A (enExample)
AU (1) AU2005210105A1 (enExample)
CA (1) CA2560055A1 (enExample)
GB (1) GB0402051D0 (enExample)
WO (1) WO2005074973A2 (enExample)
ZA (1) ZA200606331B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843222A (zh) * 2021-01-21 2021-05-28 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity
ES2367012T3 (es) * 2006-02-28 2011-10-27 Charite-Universitätsmedizin Berlin Detección y control de calidad de linfocitos t reguladores a través del análisis de metilación del adn del gen foxp3.
GB0614536D0 (en) * 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
GB0721081D0 (en) * 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
WO2011015379A1 (en) * 2009-08-05 2011-02-10 Nexigen Gbmh Human hcv-interacting proteins and methods of use
EP2887954B1 (en) 2012-08-23 2020-05-06 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions
US11369473B2 (en) 2019-04-08 2022-06-28 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis
US11779683B2 (en) * 2019-04-08 2023-10-10 Loubert S. Suddaby Extended release immunomodulatory implant to facilitate bone morphogenesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US20030165966A1 (en) * 2002-03-01 2003-09-04 Marcia Belvin MSRAs as modifiers of the p53 pathway and methods of use
GB0402051D0 (en) * 2004-01-29 2004-03-03 Metcalfe Su Fate determination in immunity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843222A (zh) * 2021-01-21 2021-05-28 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用

Also Published As

Publication number Publication date
WO2005074973A3 (en) 2005-12-08
US20070286807A1 (en) 2007-12-13
EP1713495A2 (en) 2006-10-25
ZA200606331B (en) 2007-12-27
AU2005210105A1 (en) 2005-08-18
US20080125390A1 (en) 2008-05-29
WO2005074973A2 (en) 2005-08-18
GB0402051D0 (en) 2004-03-03
WO2005074973A9 (en) 2006-10-26
CA2560055A1 (en) 2005-08-18
JP2007523640A (ja) 2007-08-23
KR20070007291A (ko) 2007-01-15

Similar Documents

Publication Publication Date Title
CN1178956C (zh) 基于癌抑制基因wt1的产物的癌抗原
CN1183968C (zh) 改良疫苗
CN1155904A (zh) Lag-3蛋白的可溶性多肽组分；生产方法、治疗组合物、抗独特型抗体
CN1805758A (zh) 核酸和细胞疫苗的组分
CN1703423A (zh) Il－15拮抗剂
CN1817367A (zh) 免疫系统的激活和抑制
CN1656216A (zh) 耐受抗原呈递细胞
CN1222536C (zh) 肝细胞癌的预防及治疗
CN1852741A (zh) 下调TGF－β效应的化合物和方法
CN1929855A (zh) 诱导或调节免疫反应的方法
CN1795206A (zh) 半乳糖凝集素－9诱导因子
CN1671836A (zh) 用于基因治疗的原代培养脂肪细胞
CN101068574A (zh) 与自身抗原有关的自身免疫和疾病的特异性抑制
CN101080420A (zh) 胸腺特异性蛋白质
CN1882603A (zh) mRNA转染的抗原呈递细胞
CN1926153A (zh) 治疗msrv/herv－w相关病理学的组合物
CN1620466A (zh) 胱氨酸结折迭蛋白质
CN1649618A (zh) 方法
CN1809589A (zh) Gitr配体和gitr配体相关分子和抗体及其应用
CN1079400A (zh) 抗肿瘤方法和抗肿瘤剂
CN1636013A (zh) 可编码hiv辅助蛋白的dna疫苗
HK1104467A (en) Method of inducing or modulating immune response
CN1948333A (zh) 一种新的hPEBP4蛋白来源的HLA－A2限制性表位多肽及其应用
HK1039565B (zh) 治疗内毒素血症的方法
CN1948475A (zh) 可用于治疗艾滋病的重组表达载体、经改造的造血干细胞和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1104467

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: EKRA CO., LTD.

Free format text: FORMER OWNER: SUSAN MARIA MEITEKAFU

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Cambridge County

Applicant after: Ekra Co. Ltd.

Address before: cambridge

Applicant before: Metcalfe Susan Marie

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070314

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1104467

Country of ref document: HK